Scholarlink

Objective <p>Preservation of visual acuity remains a challenging issue after globe sparing therapy of large uveal melanoma. The aim of our study was analyzing the functional outcome after brachytherapy with bi-nuclide plaques (BBNP), maintaining prognostic factors for legal blindness (LB).</p> Methods <p>We have analyzed all consecutive patients with large uveal melanoma treated with BBNP at our institution between 01/1999 and 12/2020. The post-treatment follow-up data were screened up to 06/2023. Univariate and multivariate Cox regression analysis was performed to identify predictive factors for development of LB following BBNP.</p> Results <p>Overall, 570 patients with median age of 65.6 years (interquartile range [IQR]: 54.5–74.0) underwent BBNP. During the median post-treatment follow-up of 30.8 months (IQR: 12.9–57.3), LB was diagnosed in 287 (50.4%) patients. Patients’ age (&gt; 67 years, adjusted hazard ratio [aHR] = 1.58, 95%-confidence interval [CI] = 1.24–2.00, <i>p</i> &lt; 0.0001), tumor thickness (&gt; 8.5&#xa0;mm, aHR = 1.43, 95%-CI = 1.12–1.82, <i>p</i> = 0.004), VA (&gt; 0.5 LogMAR, aHR = 1.59, 95%-CI = 1.25–2.02, <i>p</i> &lt; 0.0001), and ciliary body involvement (aHR = 0.77, 95%-CI = 0.60–0.97, <i>p</i> = 0.029) were confirmed as independent predictors of LB in the final multivariable Cox regression analysis.</p> Conclusions <p>Approximately a half of patients with large uveal melanoma develop LB around 2.5 years after brachytherapy. Further optimization of treatment strategies, including both therapeutic and preventive measures, has the potential to enhance the functional outcome after episcleral plaque therapy for large UMs.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Functional outcome after Brachytherapy with bi-nuclide (Ru-106/Iodine-125) plaques in large uveal melanomas

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年2月12日

查看全文
  • Leyla Jabbarli,
  • Miltiadis Fiorentzis,
  • Philipp Rating,
  • Boerge Schmidt,
  • Eva Biewald,
  • Nika Guberina,
  • Dirk Flühs,
  • Norbert Bornfeld,
  • Wolfgang Sauerwein,
  • Martin Stuschke,
  • Nikolaos E. Bechrakis,
  • Maja Guberina

摘要

Objective

Preservation of visual acuity remains a challenging issue after globe sparing therapy of large uveal melanoma. The aim of our study was analyzing the functional outcome after brachytherapy with bi-nuclide plaques (BBNP), maintaining prognostic factors for legal blindness (LB).

Methods

We have analyzed all consecutive patients with large uveal melanoma treated with BBNP at our institution between 01/1999 and 12/2020. The post-treatment follow-up data were screened up to 06/2023. Univariate and multivariate Cox regression analysis was performed to identify predictive factors for development of LB following BBNP.

Results

Overall, 570 patients with median age of 65.6 years (interquartile range [IQR]: 54.5–74.0) underwent BBNP. During the median post-treatment follow-up of 30.8 months (IQR: 12.9–57.3), LB was diagnosed in 287 (50.4%) patients. Patients’ age (> 67 years, adjusted hazard ratio [aHR] = 1.58, 95%-confidence interval [CI] = 1.24–2.00, p < 0.0001), tumor thickness (> 8.5 mm, aHR = 1.43, 95%-CI = 1.12–1.82, p = 0.004), VA (> 0.5 LogMAR, aHR = 1.59, 95%-CI = 1.25–2.02, p < 0.0001), and ciliary body involvement (aHR = 0.77, 95%-CI = 0.60–0.97, p = 0.029) were confirmed as independent predictors of LB in the final multivariable Cox regression analysis.

Conclusions

Approximately a half of patients with large uveal melanoma develop LB around 2.5 years after brachytherapy. Further optimization of treatment strategies, including both therapeutic and preventive measures, has the potential to enhance the functional outcome after episcleral plaque therapy for large UMs.